biote Corp. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $43.3 million (-9.6% year over year) and diluted EPS of $0.01. It usually reports 35–70 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 10, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Mar 11, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–70 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
From press release
|
Q3 FY2026
ended Sep 30, 2026
|
43
-9.6%
|
0
-95.0%
|
0.01
-95.5%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
44
-9.5%
|
-7
-306.1%
|
-0.23
-330.0%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
45
-8.3%
|
2
-83.4%
|
0.06
-83.8%
|
|
Mar 11, 2026
70 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
46
-6.9%
|
2
-47.2%
|
0.05
-45.3%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
48
-6.7%
|
8
-23.5%
|
0.22
-33.3%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
49
-0.6%
|
3
+144.9%
|
0.10
+147.6%
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
49
+4.7%
|
14
+429.7%
|
0.37
+408.3%
|
|
Mar 12, 2025
71 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
50
+9.0%
|
4
-52.1%
|
0.10
-56.5%
|
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- BTMD (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Irving, TX
- SEC filer status
- Accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1819253
- Former names
- Haymaker Acquisition Corp. III (until May 25, 2022)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.